Celltrion's Remsima logs $77m US sales in Q3 - (The Investor via NewsPoints Desk)

  • Sales of Remsima by Celltrion rose 8% to $77 million in the US during the third quarter, as reported The Investor on Wednesday.

  • The South Korean company did not release data on sales of the biosimilar of Janssen's Remicade in the US, where Pfizer is responsible for sales of the drug under the brand name Inflectra.

To read more NewsPoints articles, click here.

Reference Articles